Novo Nordisk A/S Class B EBIT

As of the most recent data (June 2026), NONOF shows a EBIT of $160B. That compares with $150B in the prior-year period — up 5.0% year over year. That is above the Healthcare sector average of $22B. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, NONOF's EBIT is now $160B (was $150B) — a 5.0% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Novo Nordisk A/S Class B is outperforming or lagging.

The Healthcare sector average EBIT is about $22B. Novo Nordisk A/S Class B is at $160B, which is higher that average. That is roughly 608.1% above the sector mean. Use the comparison chart on this page to see how NONOF stacks up against individual peers as well.

Tracking NONOF's ebit over time shows whether Novo Nordisk A/S Class B is scaling, shrinking, or reshaping that part of the business. The current reading is $160B That compares with $150B in the prior-year period — up 5.0% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this ebit page, Stockcircle has Novo Nordisk A/S Class B's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect EBIT (currently $160B) with ownership activity and broader fundamentals.